G
Giovanni Grignani
Researcher at University of Turin
Publications - 223
Citations - 9749
Giovanni Grignani is an academic researcher from University of Turin. The author has contributed to research in topics: Sarcoma & Medicine. The author has an hindex of 40, co-authored 189 publications receiving 7085 citations. Previous affiliations of Giovanni Grignani include University of Pavia.
Papers
More filters
Journal ArticleDOI
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Mikael Eriksson,Alexander Fedenko,Virginia Ferraresi,Andrea Ferrari,Silvia Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Maria Abbondanza Pantaleo,R. Piana,Piero Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,Eva Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
Journal ArticleDOI
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski,Sant P. Chawla,Robert G. Maki,Antoine Italiano,Hans Gelderblom,Edwin Choy,Giovanni Grignani,Veridiana Pires de Camargo,Sebastian Bauer,Sun Young Rha,Jean-Yves Blay,Peter Hohenberger,D. R. D'Adamo,Matthew Guo,Bartosz Chmielowski,Axel Le Cesne,George D. Demetri,Shreyaskumar Patel +17 more
TL;DR: Overall survival was improved in patients assigned to eribulin compared with those assigned to an active control, suggesting that eriboxin could be a treatment option for advanced soft-tissue sarcoma.
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,P. Dileo,Mikael Eriksson,Alexander Fedenko,Virginia Ferraresi,Andrea Ferrari,Silvia Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,R. L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf-Dieter Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Pantaleo,R. Piana,Piero Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,Kirsten Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,Eva Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
TL;DR: Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal; University HospitalEssen, Essen, Germany; Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome.
Journal ArticleDOI
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Mikael Eriksson,A. Fedenko,Virginia Ferraresi,Andrea Ferrari,S. Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Maria Abbondanza Pantaleo,R. Piana,P. Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,E. Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
TL;DR: Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal; University Hospital Essen, Essen Germany; Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome, Italy.
Journal ArticleDOI
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Alessandro Gronchi,Stefano Ferrari,Vittorio Quagliuolo,Javier Martin Broto,Antonio López Pousa,Giovanni Grignani,Umberto Basso,Jean-Yves Blay,Oscar Tendero,Robert Diaz Beveridge,Virginia Ferraresi,Iwona Lugowska,Domenico Franco Merlo,Valeria Fontana,Emanuela Marchesi,Davide Maria Donati,Elena Palassini,Emanuela Palmerini,Rita De Sanctis,Carlo Morosi,Silvia Stacchiotti,Silvia Bagué,Jean Michelle Coindre,Angelo Paolo Dei Tos,Piero Picci,Paolo Bruzzi,Paolo G. Casali +26 more
TL;DR: This international, open-label, randomised, controlled, phase 3, multicentre trial aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy.